Archives
-
CAR Macrophage Programming for Peritoneal Metastasis
2026-08-23
Gu and colleagues developed a macrophage-targeted mRNA lipid nanoparticle platform that programs CAR macrophages directly in the peritoneal cavity and systematically compared 36 CAR designs. The leading CD3ζ–TLR4 configuration reshaped the tumor microenvironment, increased progenitor-exhausted CD8+ T-cell activity, and enhanced the response to PD-1/L1 checkpoint therapy.
-
From Acid Mucins to Translational Readouts
2026-08-22
A mechanistic and strategic guide to using dual Alcian Blue and Nuclear Fast Red staining for mucopolysaccharide detection, chondrogenic differentiation studies, and more defensible translational workflows.
-
Nitrocefin: From Color Shift to Inhibitor Insight
2026-08-22
Nitrocefin is a chromogenic cephalosporin substrate that converts β-lactamase activity into a measurable color signal. This article explains how to move beyond simple detection by using Nitrocefin kinetics to validate computationally identified inhibitors and interpret antibiotic-resistance experiments more rigorously.
-
How p38α Conformation Controls Dephosphorylation
2026-08-21
The preprint Dual-Action Kinase Inhibitors Influence p38α MAP Kinase Dephosphorylation shows that selected inhibitors can both suppress p38α catalytic activity and accelerate removal of its activation-loop phosphate by WIP1. Its biochemical and X-ray structural analyses provide a framework for designing kinase inhibitors that control phosphatase access, although the findings remain primarily mechanistic and preclinical.
-
Nuclear cGAS–Chk2 Control of L1 Retrotransposition
2026-08-20
The reference study identifies a nuclear genome-protection pathway in which DNA damage activates Chk2, phosphorylated cGAS recruits TRIM41, and TRIM41 ubiquitinates and destabilizes L1 ORF2p. This mechanism expands cGAS biology beyond cytosolic innate immune signaling and provides a framework for studying retrotransposon control in genome instability, aging, and cancer research.
-
Dual-Action Inhibitors Reprogram p38α Dephosphorylation
2026-08-20
The reference study shows that selected kinase inhibitors can do more than suppress p38α catalytic activity: they can also accelerate removal of the activation-loop phosphate by the phosphatase WIP1. Structural comparisons explain this effect by revealing inhibitor-stabilized activation-loop conformations that expose phospho-threonine, suggesting a route toward kinase inhibitors with both direct blockade and phosphatase-assisted shutoff.
-
Phosphatase Inhibitor Cocktail 1: Lab Guide
2026-08-19
A scenario-driven guide to protein phosphorylation preservation during viability, proliferation, cytotoxicity, Western blot, and phosphoproteomic workflows. Learn how SKU K1012, Phosphatase Inhibitor Cocktail 1 (100X in DMSO), can help distinguish biological signaling changes from sample-preparation artifacts.
-
iPSC Cardiomyocytes for Chemical Hazard Prioritization
2026-08-19
The reference study demonstrates that combining transcriptomic profiles with cardiomyocyte functional measurements can improve chemical hazard identification and risk prioritization. Its concentration–response framework links electrical phenotypes, cytotoxicity, gene-expression changes, and exposure relevance without treating any single endpoint as sufficient.
-
EdU Flow Cytometry Assay Kits (Cy5) Guide
2026-08-18
EdU Flow Cytometry Assay Kits (Cy5) enable flow-cytometric measurement of DNA synthesis during a defined S-phase labeling pulse using Cy5 click chemistry. The assay is appropriate for fixed-cell proliferation, genotoxicity, and pharmacodynamic studies, but it should not be interpreted as a standalone measure of total proliferation, cell viability, or complete cell-cycle progression.
-
PDK4 Inhibitors: Discovery of Compound 8c
2026-08-18
This 2019 Journal of Medicinal Chemistry study developed an allosteric series of pyruvate dehydrogenase kinase 4 inhibitors from an anthraquinone hit, identifying compound 8c as a potent lead with an in vitro IC50 of 84 nM. The compound produced glucose-tolerance and antiallergic effects in mouse models, while metabolic, pharmacokinetic, cellular, and docking data supported further investigation of the scaffold rather than clinical validation.
-
Naloxone hydrochloride in Cell Assays
2026-08-17
This scenario-based guide explains how Naloxone (hydrochloride), SKU B8208, can be integrated into cell viability, proliferation, cytotoxicity, and opioid withdrawal research without confusing assay effects with biological mechanism. It covers controls, formulation, handling, interpretation, and practical supplier-selection criteria.
-
Alternariol and LX-2 Fibrotic Transdifferentiation
2026-08-17
The reference study shows that Alternariol (AOH) and alternariol monomethyl ether can drive LX-2 hepatic stellate cells toward a contractile, extracellular-matrix-producing myofibroblast phenotype, whereas tenuazonic acid produced no significant effect in the reported model. By combining lncRNA-mRNA omics with pathway analysis and a CotA laccase detoxification concept, the work connects Alternaria toxin exposure with liver-fibrosis biology while identifying a possible intervention strategy.
-
MDockPeP2_VS for Peptide Inhibitor Discovery
2026-08-16
A 2024 PNAS Nexus study introduces MDockPeP2_VS, a structure-based platform that combines molecular docking with structural conservation to make large-scale peptide screening more tractable. Its application to TEM-1 β-lactamase identified the peptide TF7 as a micromolar inhibitor, providing a computational starting point for antibiotic-resistance research and biochemical validation.
-
GS967 for Cardiac Late Sodium Current Studies
2026-08-15
GS967 is a selective cardiac late sodium current inhibitor for connecting ventricular myocyte electrophysiology with tissue-level arrhythmia phenotypes. Its concentration-dependent activity supports aging, ischemia, and torsades de pointes workflows while helping researchers distinguish late-current effects from broader conduction changes.
-
Optimized hiPSC Platelet Differentiation: Study Insights
2026-08-14
Yue and colleagues developed an optimized differentiation scheme that combines increased embryoid body input, human platelet lysate, cytokine-replacing small molecules, and enhanced megakaryocyte maturation. The approach generated functional platelets in 19 days, reached 14.9 platelets per iPSC, and reduced reported production costs by 58.3%, although further validation is needed for scale-up and clinical translation.